296 related articles for article (PubMed ID: 32973083)
21. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genomic profiles of small cell lung cancer.
George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies for small cell lung cancer: Where do we stand?
Arcaro A
Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
[TBL] [Abstract][Full Text] [Related]
25. The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.
Kalari S; Jung M; Kernstine KH; Takahashi T; Pfeifer GP
Oncogene; 2013 Jul; 32(30):3559-68. PubMed ID: 22907430
[TBL] [Abstract][Full Text] [Related]
26. A crucial requirement for Hedgehog signaling in small cell lung cancer.
Park KS; Martelotto LG; Peifer M; Sos ML; Karnezis AN; Mahjoub MR; Bernard K; Conklin JF; Szczepny A; Yuan J; Guo R; Ospina B; Falzon J; Bennett S; Brown TJ; Markovic A; Devereux WL; Ocasio CA; Chen JK; Stearns T; Thomas RK; Dorsch M; Buonamici S; Watkins DN; Peacock CD; Sage J
Nat Med; 2011 Oct; 17(11):1504-8. PubMed ID: 21983857
[TBL] [Abstract][Full Text] [Related]
27. Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1.
Zhao G; Gong L; Su D; Jin Y; Guo C; Yue M; Yao S; Qin Z; Ye Y; Tang Y; Wu Q; Zhang J; Cui B; Ding Q; Huang H; Hu L; Chen Y; Zhang P; Hu G; Chen L; Wong KK; Gao D; Ji H
J Clin Invest; 2019 Mar; 129(3):972-987. PubMed ID: 30688657
[TBL] [Abstract][Full Text] [Related]
28. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
29. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
[TBL] [Abstract][Full Text] [Related]
30. FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
Wang K; Ji W; Yu Y; Li Z; Niu X; Xia W; Lu S
Oncogene; 2018 Sep; 37(39):5340-5354. PubMed ID: 29858603
[TBL] [Abstract][Full Text] [Related]
31. Clinical correlation of extensive-stage small-cell lung cancer genomics.
Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
[TBL] [Abstract][Full Text] [Related]
32. Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer.
Yang F; Gao Y; Geng J; Qu D; Han Q; Qi J; Chen G
Int J Clin Exp Pathol; 2013; 6(12):2846-54. PubMed ID: 24294370
[TBL] [Abstract][Full Text] [Related]
33. FGFR1 Induces Glioblastoma Radioresistance through the PLCγ/Hif1α Pathway.
Gouazé-Andersson V; Delmas C; Taurand M; Martinez-Gala J; Evrard S; Mazoyer S; Toulas C; Cohen-Jonathan-Moyal E
Cancer Res; 2016 May; 76(10):3036-44. PubMed ID: 26896280
[TBL] [Abstract][Full Text] [Related]
34. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
35. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
Lu T; Li Z; Yang Y; Ji W; Yu Y; Niu X; Zeng Q; Xia W; Lu S
Cancer Lett; 2018 Jun; 423():36-46. PubMed ID: 29452146
[TBL] [Abstract][Full Text] [Related]
36. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.
Englinger B; Lötsch D; Pirker C; Mohr T; van Schoonhoven S; Boidol B; Lardeau CH; Spitzwieser M; Szabó P; Heffeter P; Lang I; Cichna-Markl M; Grasl-Kraupp B; Marian B; Grusch M; Kubicek S; Szakács G; Berger W
Oncotarget; 2016 Aug; 7(31):50161-50179. PubMed ID: 27367030
[TBL] [Abstract][Full Text] [Related]
37. PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.
Makinoshima H; Ishii G; Kojima M; Fujii S; Higuchi Y; Kuwata T; Ochiai A
BMC Cancer; 2012 Nov; 12():537. PubMed ID: 23170925
[TBL] [Abstract][Full Text] [Related]
38. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
[TBL] [Abstract][Full Text] [Related]
39. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
40. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
